Munich - Delayed Quote EUR

InnoCare Pharma Ltd (33C.MU)

1.2300

+0.0400

+(3.36%)

As of 8:16:36 AM GMT+2. Market Open.

InnoCare Announces the Approval of Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

BEIJING, May 21, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the China National Medical Products Administration (NMPA) has granted approval for Minjuvi® (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse

Business Wire 6 hours ago

688428.SS
Asian Equity Selections Possibly Priced Below Valuation Benchmarks For May 2025

As the Asian markets respond positively to the recent easing of U.S.-China trade tensions, investors are keenly observing opportunities that may arise from this temporary truce. In such an environment, identifying stocks potentially priced below their intrinsic value could offer strategic advantages, especially when these equities are positioned to benefit from improved economic relations and reduced tariff pressures.

Simply Wall St. 17 hours ago

SGGKF

SGGKY

9969.HK
Asian Growth Companies With High Insider Ownership

As the global markets react positively to the recent U.S.-China tariff suspension, Asian equities have shown resilience with Chinese stocks rallying on hopes of reduced trade tensions. In such a climate, identifying growth companies with substantial insider ownership can be particularly appealing, as high insider stakes often signal confidence in a company's future prospects and alignment with shareholder interests.

Simply Wall St. yesterday

MXUBY

9969.HK

AKESF
High Growth Tech Stocks To Watch In May 2025

As the global markets experience a rally fueled by positive trade developments between the U.S. and China, with key indices like the Nasdaq Composite leading gains, investors are closely watching how these changes influence high growth potential within the tech sector. In this favorable environment, identifying promising tech stocks involves focusing on companies that not only innovate but also effectively navigate international trade dynamics and inflationary pressures to sustain their...

Simply Wall St. 2 days ago

IVBIY

IVBXF

9969.HK
InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

BEIJING, May 16, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients with non-segmental vitiligo in China.

Business Wire 5 days ago

688428.SS
InnoCare’s Mesutoclax Receives Breakthrough Therapy Designation from China’s NMPA

BEIJING, May 12, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its B-cell lymphoma-2 (BCL2) inhibitor, Mesutoclax (ICP-248), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This ma

Business Wire 9 days ago

688428.SS
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA

BEIJING, May 02, 2025--InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its new generation pan-TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), which accepted the New Drug Application (NDA) of zurletrectinib for the treatment of patients with advanced solid tumors harboring NTRK gen

Business Wire 19 days ago

688428.SS
InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China

BEIJING, April 25, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). The approval of the first-line CLL/SLL treatment will enable orelabrutinib to benefit an even broader population of lymphoma patients.

Business Wire 26 days ago

688428.SS
InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China

BEIJING, April 16, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) accepted a New Drug Application (NDA) for its new generation pan-TRK inhibitor zurletrectinib (ICP-723) for the treatment of adult and adolescent patients (12 to 18 years old) with advanced solid tumors harboring NT

Business Wire last month

688428.SS
Asian Growth Companies With High Insider Ownership To Watch

Amidst global economic uncertainties and inflation concerns, Asian markets have shown resilience, with business activity in the region continuing to expand despite external pressures. In such a volatile environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong alignment between management and shareholder interests, potentially leading to more strategic decision-making during uncertain times.

Simply Wall St. last month

9969.HK

6682.HK
Exploring High Growth Tech Stocks in Asia April 2025

As the Asian markets navigate a landscape marked by global economic uncertainty and inflation concerns, investors are keeping a close eye on high-growth tech stocks that have shown resilience amid broader market volatility. In this environment, identifying promising tech stocks involves looking for companies with innovative capabilities and strong potential to adapt to changing market dynamics, which can be crucial in weathering economic challenges.

Simply Wall St. last month

9969.HK

6682.HK

2506.HK
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

BEIJING, March 28, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 (Mesutoclax) in combination with BTK inhibitor orelabrutinib as a first-line therapy for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.

Business Wire last month

688428.SS
InnoCare Releases 2024 Results and Business Highlights

BEIJING, March 27, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024.

Business Wire last month

688428.SS
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China

BEIJING, March 20, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of the Company’s novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-488, for the treatment of moderate-to-severe plaque psoriasis in China.

Business Wire 2 months ago

688428.SS
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD

BEIJING, March 09, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the data of the novel TYK2 inhibitor ICP-488 developed by the Company for the treatment of patients with moderate-to-severe plaque psoriasis has been released at the 2025 American Academy of Dermatology (AAD) Annual Meeting as a late-breaking oral presentation.

Business Wire 2 months ago

688428.SS
Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum

BEIJING, February 26, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase II results of orelabrutinib for the treatment of relapsing-remitting multiple sclerosis (RRMS) was released at the 10th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, which will be also presented as the on-site poster on Feb. 27 U.S. Eastern Time.

Business Wire 2 months ago

688428.SS
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

BEIJING, February 17, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the registrational Phase III clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 (Mesutoclax) in combination with BTK inhibitor orelabrutinib as a first-line therapy for the treatment of chronic

Business Wire 3 months ago

688428.SS
InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02

BEIJING, January 20, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) today announced that the two companies, together with their joint venture, have jointly entered into an exclusive license agreement with Prolium Bioscience (Prolium) for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Business Wire 3 months ago

688428.SS
Latest Data of InnoCare’s Orelabrutinib Presented at the 66th Annual Meeting of ASH

BEIJING, December 09, 2024--Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the ongoing 66th American Society of Hematology (ASH) Annual Meeting.

Business Wire 5 months ago

688428.SS
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

BEIJING, November 15, 2024--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in the Phase III registrational trial of the Company's novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 for the treatment of atopic dermatitis (AD) in China.

Business Wire 6 months ago

688428.SS

Performance Overview

Return	33C.MU	HANG SENG INDEX (^HSI)
YTD	+66.22%	+18.78%
1-Year	+106.72%	+23.97%
3-Year	--	+15.01%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

InnoCare Pharma Ltd (33C.MU)

InnoCare Announces the Approval of Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

Asian Equity Selections Possibly Priced Below Valuation Benchmarks For May 2025

Asian Growth Companies With High Insider Ownership

High Growth Tech Stocks To Watch In May 2025

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

InnoCare’s Mesutoclax Receives Breakthrough Therapy Designation from China’s NMPA

InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA

InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China

InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China

Asian Growth Companies With High Insider Ownership To Watch

Exploring High Growth Tech Stocks in Asia April 2025

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

InnoCare Releases 2024 Results and Business Highlights

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China

Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD

Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum

InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02

Latest Data of InnoCare’s Orelabrutinib Presented at the 66th Annual Meeting of ASH

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Performance Overview